Mayne Pharma Group Says Fiscal 2026 H1 Unaudited Revenue Falls 0.5% Year on Year
MT Newswires Live
Jan 29
Mayne Pharma Group (ASX:MYX) said its unaudited revenue for the fiscal 2026 first half came in at AU$212.1 million, down 0.5% from the result it reported in the year-ago period, according to a Thursday Australian bourse filing.
Its unaudited underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) for the period clocked in at AU$28.6 million, down 8% year-over-year from AU$31 million in the first half of fiscal year 2025.
It cited a lower contribution from the women's health segment, as well as additional investment into sales activities, as drivers behind the underlying EBIDTA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.